Cargando…

PB2360: HIV-ASSOCIATED BURKITT LYMPHOMA IN THE COMBINATION ANTIRETROVIRAL THERAPY ERA: REAL-WORLD OUTCOMES AND PROGNOSTICATION

Detalles Bibliográficos
Autores principales:	Wang, Chaoyu, Liu, Jieping, Liu, Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428778/ http://dx.doi.org/10.1097/01.HS9.0000976156.18103.7b

Ejemplares similares

HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication
por: Wang, Chaoyu, et al.
Publicado: (2022)

PB2135: BURKITT LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (BL-IPI): IS IT EFFICIENT ENOUGH IN ADULT BURKITT LYMPHOMA PATIENTS?
por: Sayinalp, B., et al.
Publicado: (2022)

PB2360: QUALITY OF LIFE AND TREATMENT SATISFACTION AMONG PATIENTS UNDER LONG-TERM ANTICOAGULANT THERAPY WITH VITAMIN K ANTAGONISTS
por: Varaklioti, A., et al.
Publicado: (2022)

PB2143: CLINICAL CHARACTERISTICS AND PROGNOSTIC FEATURES OF 63 HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER REAL-WORLD STUDY IN CHINA
por: Wang, C., et al.
Publicado: (2022)

PB2300: IMPACT OF INITIAL CHEMOTHERAPY CYCLES AND CLINICAL CHARACTERISTICS ON OUTCOMES FOR HIV-ASSOCIATED DIFFUSE LARGE B CELL LYMPHOMA PATIENTS: THE CENTRAL AND WESTERN CHINA AIDS LYMPHOMA LEAGUE STUDY
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2332: CLINICAL CHARACTERISTICS AND OUTCOMES OF HIV-ASSOCIATED AGGRESSIVE B-CELL NHL IN CHINA
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2274: REAL-WORLD OUTCOME OF FOLLICULAR LYMPHOMA IN TAIWAN: A MULTICENTER REGISTRY STUDY
por: Ko, Bor-Sheng, et al.
Publicado: (2023)

PB2365: CHILDHOOD BURKITT LYMPHOMA: ABOUT 31 CASES (EXPERIENCE OF THE PEDIATRIC CLINICAL HEMATOLOGY DEPARTMENT OF AZIZA OTHMANA’S HOSPITAL)
por: Rihab, Nefzi, et al.
Publicado: (2023)

PB2399: BRENTUXIMAB VEDOTIN IN TREATING CHINESE PATIENTS WITH LYMPHOMA:A MULTICENTER,REAL-WORLD STUDY
por: Zhang, Xudong, et al.
Publicado: (2023)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

PB1957: PROGNOSTIC SIGNIFICANCE OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH IGHV-U IN THE ERA OF NOVEL AGNETS; REAL-LİFE DATA
por: Arikan, Fatma, et al.
Publicado: (2023)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB2606: REAL-WORLD EXPERIENCE OF HETROMBOPAG IN RELAPSE AND REFRACTORY IMMUNE THROMBOCYTOPENIA
por: Feng, Yimei, et al.
Publicado: (2023)

PB2293: REAL WORLD STUDY OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE ELDERLY: FOURTEEN YEARS OF ONE CENTER’S EXPERIENCE
por: De Ascanio, Victoria Ramos, et al.
Publicado: (2023)

PB2303: REAL-WORLD TREATMENT PATTERNS AND ADVERSE EVENTS AMONG PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A RETROSPECTIVE DATABASE STUDY
por: Dharmani, Charles, et al.
Publicado: (2023)

PB2262: PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKINN LYMPHOMA
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2281: TRIAL IN PROGRESS: FOLLICULAR LYMPHOMA OUTCOMES IN RELAPSED/REFRACTORY PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA)
por: Damaj, Gandhi Laurent, et al.
Publicado: (2023)

PB2142: CLINICAL CHARACTERISTICS AND OUTCOMES OF NEWLY DIAGNOSED PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED LYMPHOMA ADMINISTERED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
por: Wang, C., et al.
Publicado: (2022)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Xiaomei, et al.
Publicado: (2023)

PB2148: EFFICACY OF SMALL MOLECULE TARGET THERAPIES IN REFRACTORY OR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AND MOLECULAR SUBTYPING: A MULTI-CENTER REAL-WORLD EVIDENCE
por: Zhang, Y., et al.
Publicado: (2022)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB2298: CHRONIC HEPATITIS B VIRAL ACTIVITY IS AN INDEPENDENT PROGNOSTIC FACTOR OF LYMPHOMA
por: Lee, Ho Sup, et al.
Publicado: (2023)

PB2610: EPIDEMIOLOGY AND TREATMENT OF ITP: A SINGLE CENTRE, REAL-WORLD EXPERIENCE
por: Patel, Priya, et al.
Publicado: (2023)

PB1896: ACUTE MYELOID LEUKEMIA (AML): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1734: SURVIVAL OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN ECUADOR. AN ANALYSIS OF THE REAL WORLD
por: Sabando, Brenner, et al.
Publicado: (2023)

PB2306: REAL-WORLD FIRST-LINE TREATMENT AND OUTCOMES AMONG PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD OF CARE
por: Yan, Jiali, et al.
Publicado: (2023)

PB2363: R-MPV FOLLOWED BY CONSOLIDATION REDUCED-DOSE WHOLE-BRAIN RADIOTHERAPY AND CYTARABINE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: REAL WORLD DATA
por: Amani, Maha EL, et al.
Publicado: (2023)

PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID)
por: Thieblemont, Catherine, et al.
Publicado: (2023)

PB2313: THE PROGNOSTIC SIGNIFICANCE OF APOPTOSIS-INDUCING FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Vaneeva, Elena, et al.
Publicado: (2023)

PB2028: TREATING MULTIPLE MYELOMA IN A RESOURCE-LIMITED SETTING: REAL-WORLD OUTCOMES
por: Martinez, G., et al.
Publicado: (2022)

PB2105: LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA: A RETROSPECTIVE, NATIONWIDE, REAL-WORLD STUDY
por: Harsløf, Mads, et al.
Publicado: (2023)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Komrokji, Rami S., et al.
Publicado: (2023)

PB2065: IMPORTANCE OF PET AS A PROGNOSTIC MARKER IN TREATMENT STRATEGY CHOICE IN PATIENTS WITH HODGKIN LYMPHOMA
por: Novosad, O., et al.
Publicado: (2022)

PB2354: DIFFUSE LARGE B CELL LYMPHOMA IN 65: DIAGNOSTIC, PROGNOSTIC, PROGRESSIVE AND THERAPEUTIC ASPECTS
por: Mlayah, Zaineb, et al.
Publicado: (2023)

PB2270: PROGNOSTIC VALUE OF INTERIM POSITRON EMISSION TOMOGRAPHY IN HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA
por: Argumánez, Marta Mora, et al.
Publicado: (2023)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sa02u6j7r9mqdvn0v8o9a0r1a7